Episodes

  • "MitraClip Procedure Overview"

    "MitraClip Procedure Overview"
    Jul 19 2025
    Authored by Dr. Reza Lankarani, General Surgeon MitraClip™ is a minimally invasive transcatheter edge-to-edge repair (TEER) device designed to treat mitral regurgitation (MR), a condition where the mitral valve fails to close properly, causing blood to leak backward into the heart. Inspired by the Alfieri surgical technique, which sutures the valve leaflets to create a double orifice, the MitraClip uses a small metal clip to grasp and coapt the leaflets, reducing regurgitation . It is the first FDA-approved transcatheter mitral valve repair therapy and has been used in over 200,000 patients globally.------------------------------------------------------------Indications: - Primary (Degenerative) MR: For patients at prohibitive surgical risk due to age, frailty, or comorbidities (e.g., severe COPD, renal failure) . - Secondary (Functional) MR: For patients with heart failure and persistent symptoms despite optimal guideline-directed medical therapy (GDMT), LVEF 20–50%, and LVESD ≤70 mm . Contraindications:- Active endocarditis, rheumatic mitral disease, or blood clots in the heart/inferior vena cava . - Allergies to device materials (nickel, titanium, polyester) or inability to tolerate anticoagulation .------------------------------------------------------------Procedure Overview: The MitraClip procedure is performed under general anesthesia with fluoroscopic and transesophageal echocardiography (TEE) guidance.Key steps include: 1. Transseptal Puncture: Accessing the left atrium via the femoral vein, with the puncture site optimized for clip alignment . 2. Clip Delivery: A steerable catheter guides the clip to the mitral valve. The clip is opened, advanced into the left ventricle, and used to grasp the leaflets . 3. Assessment: Real-time TEE evaluates regurgitation reduction and mitral stenosis risk (target gradient ≤5 mmHg). Additional clips may be placed if needed . 4. Deployment: The clip is released, and the catheter is withdrawn. Most procedures take 1–3 hours, with a hospital stay of 1–3 days .------------------------------------------------------------Clinical Outcomes: - Survival and Hospitalization: - In the COAPT trial, MitraClip reduced heart failure hospitalizations by 47–51% and mortality risk by 33% over 2–3 years . - Patients with secondary MR showed improved survival compared to medical therapy alone . - Quality of Life: - 2.5× higher likelihood of significant improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores . - Symptoms like shortness of breath and fatigue improved in 95% of cases . - Durability: - EVEREST II trial demonstrated sustained MR reduction and reverse LV remodeling at 5 years . Risks and Complications:- Procedural Risks: - Vascular complications (3–13% requiring transfusion), atrial septal defects, or pericardial effusion . - Single-leaflet detachment (1–3%) or device embolization (rare) . - Post-Procedural Risks: - Mitral stenosis (if gradients exceed 5 mmHg) or residual MR . - Overall 30-day complication rate: 15–19% Device Innovations:The MitraClip G4 System (4th generation) offers: - Four Clip Sizes: NT (9 mm), NTW (12 mm), XT (15 mm), and XTW (18 mm) for tailored repairs . - Controlled Gripper Actuation: Allows independent leaflet grasping for complex anatomies . - Enhanced Imaging Integration: Improved delivery system stability for precise placement . ------------------------------------------------------------Guidelines and Recommendations:- 2022 AHA/ACC/HFSA Guidelines: Class 2a recommendation for TEER in secondary MR patients with LVEF 20–50% and persistent symptoms despite GDMT . - Patient Selection: Requires a multidisciplinary heart team to evaluate surgical risk, anatomy, and comorbidities . Post-Procedure Care:- Medications: Aspirin (lifelong) and clopidogrel (30 days) for antiplatelet therapy; anticoagulants for atrial fibrillation . - Activity Restrictions: Avoid strenuous activity for 7 days; follow-up echocardiograms at 30 days and annually . ------------------------------------------------------------Conclusion:MitraClip™ represents a paradigm shift in treating MR for high-risk patients, offering survival benefits, symptom relief, and faster recovery compared to surgery. Ongoing innovations, such as the G4 system, continue to expand its applicability. However, careful patient selection and procedural expertise remain critical for success . Reza Lankarani M.D#mitraclip#mitraclip procedure#mitraclip therapy#mitral valve repair#minimally invasive heart procedure#mitral regurgitation#heart valve treatment#interventional cardiology#cardiac catheterization#mitraclip benefits#mitraclip risks#mitraclip recovery#mitraclip screening#mitraclip procedure steps#heart health#valve repair surgery #Surgical Pioneering #Reza Lankarani Get full access to Reza Lankarani at lankarani.substack.com/subscribe
    Show More Show Less
    22 mins
  • "Association Between Triglyceride-Glucose Index and Breast Cancer: A Systematic Review and Meta-Analysis"

    "Association Between Triglyceride-Glucose Index and Breast Cancer: A Systematic Review and Meta-Analysis"
    Jul 18 2025

    Reviewed by Reza Lankarani M.D

    ------------------------------------------------------------

    Zooravar et al., Cancer Reports (2025)

    https://doi.org/10.1002/cnr2.70194

    ------------------------------------------------------------

    This academic article presents a systematic review and meta-analysis examining the Triglyceride-Glucose (TyG) index in relation to breast cancer. It evaluates the TyG index as a potential indicator for breast cancer risk, progression, and its ability to differentiate between malignant and benign breast lesions. While cohort studies did not establish a strong predictive link for initial breast cancer development, case-control and cross-sectional studies suggested a significant association between elevated TyG index and increased risk. The research highlights the TyG index's utility in distinguishing malignant from benign lesions, proposing its value as an accessible diagnostic tool in clinical settings.

    Conclusion

    This review strengthens TyG’s role as a metabolic biomarker for BC diagnosis, particularly in distinguishing malignant lesions. While cohort studies refute its utility for risk prediction, TyG reflects tumor-driven metabolic dysfunction with implications for prognosis. For surgical practice, TyG could optimize preoperative stratification and postoperative metabolic management. Future studies should prioritize standardized thresholds and validate TyG in multimodal diagnostic algorithms.

    Reza Lankarani M.D



    Get full access to Reza Lankarani at lankarani.substack.com/subscribe
    Show More Show Less
    12 mins
  • "Burns and Mental Health: A Matched Cohort Study"

    "Burns and Mental Health: A Matched Cohort Study"
    Jul 16 2025

    Reviewed by Reza Lankarani M.D

    ------------------------------------------------------------

    Published online June 2025

    DOI: 10.1097/SLA.0000000000006270

    Annals of Surgery

    ------------------------------------------------------------

    This large-scale matched cohort study investigates the long-term association between burn injuries and mental health hospitalizations over 33 years. Analyzing 23,726 burn patients and 223,626 controls from Quebec, Canada, the study found that burn survivors had a 1.76-fold increased risk of mental health hospitalization compared to controls, with risks persisting up to 30 years post-injury. Severe burns (≥50% body surface area, third-degree burns, skin graft requirements) were linked to higher risks (HR: 2.00–3.29). Notably, burn patients exhibited elevated risks for eating disorders (HR: 3.14), substance use disorders (HR: 2.27), and suicide attempts (HR: 2.42), particularly within the first 5 years after injury.

    Comprehensive Data Linkage:

    - Utilizing population-based registries allowed for accurate tracking of hospitalizations and covariates, including socioeconomic status and preexisting conditions. This reduces selection bias and enhances generalizability within publicly funded healthcare systems.

    Subgroup Analyses:

    - Detailed stratification by burn severity (e.g., body surface area, degree, graft requirements) and mental health outcomes strengthens the validity of associations. For example, severe burns requiring grafts showed a 2-fold higher risk of hospitalization, highlighting the dose-response relationship between injury severity and mental health outcomes .

    -----------------------------

    Comparison with Recent Studies:

    - Short-Term vs. Long-Term Risk:

    Earlier studies (e.g., Bich et al., 2021) reported elevated psychiatric risks up to 5 years post-burn , while this study extends the timeline to 30 years, corroborating longitudinal data from Abouzeid et al. (2022) on chronic mental health decline .

    - Severity Gradient:

    Consistent with Logsetty et al. (2016), severe burns requiring grafts showed the highest mental health risks, emphasizing the need for targeted interventions in this subgroup .

    - Substance Use Disorders:

    The observed 2.14-fold increased risk for alcohol-related hospitalizations aligns with Mason et al. (2017), who linked burn-related chronic pain and opioid prescriptions to substance misuse .

    -------------------------------

    In conclusion, this study exemplifies the value of population-based cohort designs in uncovering the chronic impacts of surgical conditions. It sets a foundation for future research aimed at improving holistic burn care. Burn units should adopt lifelong mental health monitoring protocols, with intensified surveillance in the first 5 years post-injury. Pain management strategies must balance efficacy with addiction prevention to mitigate substance use risks .

    --

    Reza Lankarani M.D

    #burnsandmentalhealth #mentalhealthresearch #burninjurypsychologicalimpact #burnsurvivorsmentalhealth #mentalhealthstudy #cohortstudy #burntraumaandpsychology #psychologicaleffectsofburns #mentalhealthsupport #burninjuryrecovery #mentalhealthawareness #traumaandmentalhealth #psychologicalresilienceburns #burninjurymentalhealthanalysis #healthresearch #mentalhealthoutcomes #burnrehabilitation #mentalhealthinterventions #healthcareresearch



    Get full access to Reza Lankarani at lankarani.substack.com/subscribe
    Show More Show Less
    2 mins
  • "Comparison Between Endovascular and Surgical Treatment of Acute Arterial Occlusive Mesenteric Ischemia"

    "Comparison Between Endovascular and Surgical Treatment of Acute Arterial Occlusive Mesenteric Ischemia"
    Jul 15 2025

    Reviewed by Reza Lankarani MD

    -------------------------

    World Journal of Emergency Surgery

    https:/doi.org/10.1186/s13017-025-00616-4

    This prospective observational substudy of the AMESI cohort provides valuable insights into the complex management of acute arterial occlusive mesenteric ischemia (AMI), specifically superior mesenteric artery (SMA) occlusion. Crucially, the authors rigorously account for baseline severity of illness (APACHE II, SOFA, lactate, vasopressor/ventilator needs), a major confounder often inadequately addressed in prior literature.

    Their sophisticated statistical approach, including multivariable logistic regression adjusted for key severity markers, robustly demonstrates that the apparent mortality benefit of endovascular therapy in unadjusted analysis (15.7% vs. 45.8%) is largely attributable to patient selection favoring less severely ill patients for endovascular intervention.

    The finding that neither initial treatment modality (endovascular vs. surgical) nor the performance of revascularization itself was an independent predictor of mortality after adjustment challenges simplistic interpretations of previous retrospective data and guideline recommendations.

    The subgroup analysis of endovascular monotherapy effectiveness (66.6% success rate) and its stark mortality difference (2.9% effective vs. 41.2% insufficient) provides clinically relevant granularity, highlighting the critical importance of patient selection for this approach.

    The explicit inability to identify reliable time thresholds or lactate cut-offs (beyond normal ranges) for predicting endovascular success underscores the complexity of AMI pathophysiology and the limitations of isolated biomarkers or symptom duration in guiding therapy.

    The study's significant strengths are its prospective nature, adjustment for illness severity, multicenter representation, and transparent reporting of limitations.

    However, key limitations acknowledged by the authors must be considered: inherent selection bias in treatment assignment within an observational design, relatively small subgroup sizes (especially for failed endovascular monotherapy, n=17), potential heterogeneity in treatment protocols across centers, and missing data for severity scores in some patients.

    Despite these limitations, the study makes a substantial contribution by shifting the paradigm: it compellingly argues that the choice between endovascular and surgical intervention should prioritize the patient's overall physiological condition and the etiology of occlusion (embolism vs. thrombosis) over rigid adherence to symptom duration thresholds. It sets a crucial precedent for future studies by emphasizing the absolute necessity of detailed reporting and adjustment for baseline severity, symptom duration, and AMI subtype to generate truly evidence-based management guidelines.

    -----------------------------------

    Reza Lankarani M.D

    #endovasculartreatment #surgicaltreatment #arterialocclusivemesentericischemia #acutemesentericischemia #vascularsurgery #minimallyinvasivesurgery #mesentericischemiamanagement #endovasculartherapy #surgicalintervention #mesentericartery #ischemiadiagnosis #vascularintervention #emergencybowelischemia #treatmentcomparison #mesentericischemiaoutcomes



    Get full access to Reza Lankarani at lankarani.substack.com/subscribe
    Show More Show Less
    2 mins
  • "Vagilangelo, Innovation or Exploitation in Women’s Health Deep Dive Podcast"

    "Vagilangelo, Innovation or Exploitation in Women’s Health Deep Dive Podcast"
    Jul 13 2025
    The provided sources, primarily critiques from an OBGYN and health disparities researcher, Dr. Reza Lankarani, highlight significant concerns regarding the Vagilangelo® procedure and the broader landscape of cosmetic gynecology, particularly in the context of medical tourism and training in Arab countries. The central theme revolves around the tension between profit-driven healthcare and patient safety, arguing that the commercialization of uncertainty in women's health is exploitation, not innovation.1. The Vagilangelo® Procedure: Unsubstantiated Claims and Evidence DeficitThe Vagilangelo® procedure, marketed as a revolutionary vaginal rejuvenation technique, aims to restore "natural vaginal angulation" through internal suturing and platelet-rich plasma (PRP) injections. However, the sources assert that its claims are largely unsubstantiated by scientific evidence.Lack of Peer-Reviewed Validation: Despite claims of "77% satisfaction," Dr. Lankarani's critical review notes: "High satisfaction rates cited are anecdotal... Clinical trials comparing it to established methods would significantly strengthen its standing." The procedure lacks "zero randomized controlled trials," "no longitudinal safety data," and "absence of objective outcome measures (e.g., validated sexual function scales)."Unproven Biological Mechanisms: The efficacy of PRP for vaginal sensitivity lacks "tissue-specific evidence," and its growth factor concentrations and injection protocols are not standardized. This "scientific overreach" contrasts with established therapies that have documented effects.Inadequate Structural Correction: Marketing materials state Vagilangelo® provides "less tightening than traditional vaginoplasty," making it unsuitable for significant prolapse or laxity, positioning it as a "solution" for problems it cannot adequately address.Unquantified Risks: Unlike traditional surgeries with documented complication rates (e.g., vaginoplasty stenosis rates: 5–15% at 5 years), Vagilangelo® lacks published data on intraoperative risks, long-term safety, or pain management. The use of internal sutures poses theoretical risks of "urethral/bladder injury" and "nerve damage."2. The Exploitative Ecosystem: Medical Tourism and Predatory TrainingThe sources heavily criticize the "exploitative cosmetic surgery tourism" and "unethically trained practitioners" associated with procedures like Vagilangelo®, particularly targeting vulnerable women in low-resource settings like Bahrain.Medical Tourism's Hidden Costs: Bahrain's experience shows that its tertiary centers absorb significant costs (175,000 USD annually) treating complications from cosmetic tourism, mostly infections and implant failures. "All-inclusive packages" typically exclude meaningful postoperative care, leading to "patient abandonment" and an "economic drain" on local healthcare systems.Unethical Training Paradigms: The rise of "short-course 'fellowships'" (e.g., 3-5 day "certification" programs in Arab countries) enables this crisis. These programs lack "standardized curricula" and bypass the 1-2 years of supervised training required for legitimate surgical fellowships. They are accused of "targeting vulnerable populations" and allowing "underqualified surgeons operating on poor women," which is deemed "ethical malpractice."Commercialization of Insecurity: Vagilangelo® marketing is seen as violating core bioethical principles by prioritizing profit over documented clinical benefit. Patients cannot provide meaningful consent due to a lack of outcome data, and the high cash-pay cost ($3,000+) excludes low-income women who might need functional repair.3. Ethical Violations and Health DisparitiesThe commercialization of procedures without robust evidence is seen as contributing to global health inequity and ethical failures.Autonomy Violation: Patients cannot provide meaningful consent without comprehensive, evidence-based information on risks and benefits.Justice Failure: The high cost excludes low-income women who might benefit more from affordable, evidence-based functional repairs.Beneficence Abandonment: The emphasis on profit over documented clinical benefit is a betrayal of the medical principle of beneficence.Regressive Healthcare Subsidy: Public hospitals bear the burden of complications from offshore cosmetic procedures, effectively subsidizing a profit-driven industry.4. Policy Recommendations: Toward Ethical PracticeThe sources propose a multi-faceted approach to address these issues, emphasizing regulatory harmonization, patient safety integration, and ethical commercialization.Evidence and Regulation Reform: This includes an "immediate moratorium on Vagilangelo® marketing pending RCTs," standardization of outcome measures by professional bodies (e.g., ACOG/FIGO), and "FDA-equivalent oversight of PRP preparation protocols."Training and Equity Measures: Recommendations include a "global ban on <3-month cosmetic surgery 'fellowships'," mandatory ...
    Show More Show Less
    14 mins
  • Vagilangelo, Innovation or Exploitation in Women’s Health?

    Vagilangelo, Innovation or Exploitation in Women’s Health?
    Jul 11 2025
    Authored by Reza Lankarani MD Section 1: IntroductionCosmetic gynecology is a rapidly growing field, fueled by technological advances and increasing societal interest in aesthetic and functional modifications of female genital anatomy. Among these innovations, Vagilangelo® is heavily marketed as a revolutionary, minimally invasive vaginal rejuvenation technique promising to restore the "natural vaginal angle" disrupted by childbirth or aging, with purported benefits in sexual satisfaction and sensitivity.However, beneath its glossy promotional veneer lies a complex web of scientific uncertainties, ethical dilemmas, and health equity challenges. Today, we will dissect these layers with academic rigor and clinical insight to provide you, our listeners, with a nuanced understanding of Vagilangelo®’s place in modern gynecological practice.Section 2: Critical Scientific Weaknesses and Evidence GapsThe most significant issue surrounding Vagilangelo® is the stark absence of rigorous clinical evidence. Unlike well-established vaginal rejuvenation procedures documented in peer-reviewed journals such as The Journal of Sexual Medicine or the American Journal of Obstetrics and Gynecology, Vagilangelo® relies almost exclusively on manufacturer websites and patient testimonials for its claims. There are no Level I to III studies—meaning no randomized controlled trials, cohort studies, or even case series—to definitively prove its efficacy or safety.As Dr. Reza Lankarani, a respected clinical researcher, has emphasized, this lack of high-quality evidence is a glaring flaw that undermines the procedure’s credibility. In contrast, other less invasive modalities such as laser or radiofrequency (RF) therapies for vaginal rejuvenation have at least preliminary clinical data supporting their use.Furthermore, the biological rationale for the use of PRP injections in Vagilangelo® is problematic. Platelet-Rich Plasma has demonstrated efficacy in some medical fields, such as orthopedics, but its role in vaginal tissue regeneration and sensitivity enhancement remains unproven. Scientific literature, including recent studies published in journals like Cells in 2023, highlights the variability in PRP composition, the lack of standardized injection protocols, and conflicting results regarding its benefits for vaginal lubrication or sensitivity.Beyond these biological uncertainties, Vagilangelo® does not adequately address key structural issues. The procedure explicitly avoids correction of pelvic floor musculature or significant ligamentous laxity, which are often involved in pelvic organ prolapse or functional disorders. Marketing materials themselves acknowledge that Vagilangelo® offers less tightening than traditional vaginoplasty—rendering it unsuitable for patients with moderate to severe pelvic floor dysfunction.Finally, the risks associated with Vagilangelo® are frequently downplayed. Although marketed as “non-invasive,” internal suturing near delicate pelvic nerves and organs carries inherent risks such as suture erosion, chronic pain (dyspareunia), and urinary symptoms (dysuria). PRP injections may also cause complications like infection, scarring, or paradoxical pain. Post-procedural care often requires sexual abstinence for several weeks, mirroring surgical aftercare, yet standardized protocols for managing complications are lacking.---Section 3: Comparative Limitations Against Established AlternativesIn the landscape of vaginal rejuvenation, Vagilangelo® occupies an ambiguous niche. It is less invasive than traditional surgical options like vaginoplasty but more invasive than energy-based modalities such as laser or radiofrequency therapies.Energy-based devices have the advantage of inducing collagen remodeling with documented histological evidence and relatively low risk profiles, without the need for suturing. Vaginoplasty, on the other hand, is the gold standard for correcting severe anatomical defects, with decades of outcome and safety data.Vagilangelo® lacks the evidence base, functional scope, and risk-mitigation protocols of these traditional methods. It is neither a substitute for surgery nor a clearly superior alternative to energy-based treatments. This “middle ground” status complicates clinical decision-making and patient counseling.---Section 4: Ethical Concerns and Commercial ExploitationTurning to the ethical dimension, Vagilangelo® raises serious concerns about the commercialization of women’s health insecurities. The procedure is heavily marketed using terms like “revolutionary” and “groundbreaking,” which can create unrealistic expectations among vulnerable populations—particularly postpartum women who may be distressed by natural anatomical changes after childbirth.This marketing strategy violates ethical standards such as the American Medical Association’s Code of Medical Ethics §8.063, which stresses the importance of providing patients with realistic ...
    Show More Show Less
    2 mins
  • GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift?

    GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift?
    Jul 8 2025

    GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift?

    1.1. Host: Obesity and diabetes management are seeing a seismic shift, Dr. Lankarani, with GLP-1 agonists like semaglutide making headlines. Is metabolic surgery becoming obsolete, or do these drugs complement existing surgical interventions?

    1.2. Guest: It's a critical juncture. While GLP-1 drugs offer noninvasiveness and 15–22% weight loss, bariatric surgery still outperforms in durability—delivering over 25% weight loss and diabetes remission in 80% of patients, as shown in STAMPEDE trial's 10-year data, which all these databases gatheredby by Dr Reza Lankarani, General Surgeon and Surgical Innovation Lead, Curator and Founder of Surgical Pioneering Newsletter and Podcast Series.

    1.3. Host: Yet, for some patients—especially those with BMI 30–35 or unwilling to undergo surgery—GLP-1s seem transformative. Real-world studies like SURMOUNT-4 highlight better adherence and lower complication rates. How should clinicians weigh these benefits against surgical options?

    1.4. Guest: Patient selection is key. Surgery addresses metabolic drivers beyond appetite suppression, but GLP-1s provide a cost-effective, accessible route for those at lower risk. The real challenge lies in balancing short-term drug trial data with proven surgical longevity.

    1.5. Host: So, as these therapies evolve, will we see more combination protocols or a clearer division between surgical and pharmacologic candidates?

    1.6. Guest: Combination strategies may soon emerge, particularly as we integrate longer-term GLP-1 outcomes. Ultimately, multidisciplinary teams must tailor approaches based on comorbidities, prior weight loss attempts, and patient preference.

    #generalsurgerycontroversies #surgicalethicsdebates #medicalmalpracticecases #invasivevsminimallyinvasivesurgery #surgicalinnovationcontroversies #patientsafetyinsurgery #surgicalguidelinesdebate #surgeonaccountabilityissues #healthcarepolicysurgery #surgicaltrainingcontroversies #postoperativecomplicationissues #surgicaltechnologydebates #surgeon-patientcommunication #surgicalriskmanagement #recentsurgicalscandals #surgicalPioneering glp-1 agonists #metabolic surgery #obesity management #weight loss strategies #type 2 diabetes treatment #bariatric procedures #gut hormones #semaglutide #liraglutide #wegovy #satiety regulation #appetite control #diabetes and obesity #future of obesity treatment #surgical vs medical obesity options



    Get full access to Reza Lankarani at lankarani.substack.com/subscribe
    Show More Show Less
    1 min
  • "Top 5 Controversies in General Surgery for 2024–2025"

    "Top 5 Controversies in General Surgery for 2024–2025"
    Jul 7 2025
    Authored by Reza Lankarani, M.D General surgery faces intense debates for 2024–2025, including GLP1 agonists vs. bariatric surgery, bridging anticoagulation in urgent cancer surgery, timing of hip fracture repair in heart failure patients, robotic vs. laparoscopic surgery costs and benefits, and opioid-sparing pain protocols. Key issues revolve around clinical outcomes, evolving technology, cost-effectiveness, patient safety, and ethical challenges in modern surgical care. 1. GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift? 1.1. Host: Obesity and diabetes management are seeing a seismic shift, Dr. Lankarani, with GLP-1 agonists like semaglutide making headlines. Is metabolic surgery becoming obsolete, or do these drugs complement existing surgical interventions? 1.2. Guest: It's a critical juncture. While GLP-1 drugs offer noninvasiveness and 15–22% weight loss, bariatric surgery still outperforms in durability—delivering over 25% weight loss and diabetes remission in 80% of patients, as shown in STAMPEDE trial's 10-year data, which all these databases gatheredby by Dr Reza Lankarani, General Surgeon and Surgical Innovation Lead, Curator and Founder of Surgical Pioneering Newsletter and Podcast Series. 1.3. Host: Yet, for some patients—especially those with BMI 30–35 or unwilling to undergo surgery—GLP-1s seem transformative. Real-world studies like SURMOUNT-4 highlight better adherence and lower complication rates. How should clinicians weigh these benefits against surgical options? 1.4. Guest: Patient selection is key. Surgery addresses metabolic drivers beyond appetite suppression, but GLP-1s provide a cost-effective, accessible route for those at lower risk. The real challenge lies in balancing short-term drug trial data with proven surgical longevity. 1.5. Host: So, as these therapies evolve, will we see more combination protocols or a clearer division between surgical and pharmacologic candidates? 1.6. Guest: Combination strategies may soon emerge, particularly as we integrate longer-term GLP-1 outcomes. Ultimately, multidisciplinary teams must tailor approaches based on comorbidities, prior weight loss attempts, and patient preference. 2. Bridging Anticoagulation in Cancer Surgery: Bleeding or Stent Risk? 2.1. Host: Let’s move to urgent cancer surgery in patients with recent coronary stents. The debate over bridging with IV cangrelor versus aspirin alone is intensifying. Where does current evidence stand, and how do we reconcile registry data with randomized trials? 2.2. Guest: Registry data suggest bridging increases bleeding and cost without clear benefit, especially with modern drug-eluting stents lowering thrombosis risk to under 1% after 30 days. The CHAMPION PHOENIX trial did show cangrelor’s rapid reversibility, but at a steep $5,000 per dose. 2.3. Host: Still, in patients with high-risk anatomy, like left main stents, some guidelines support bridging. Is this a case where individualized anatomy and oncology timelines should override blanket protocols? 2.4. Guest: Precisely. While guidelines now favor aspirin-only post 1 month, nuanced decisions must consider stent location, cancer urgency, and patient-specific risks. Value-based care demands we weigh bleeding complications against rare but catastrophic stent thrombosis. 2.5. Host: Do you anticipate consensus shifting as more real-world data accumulates, or will this remain a case-by-case decision? 2.6. Guest: It’s likely to stay individualized, but ongoing registry analyses and RCTs will refine protocols—perhaps with newer reversal agents or tailored risk calculators. 3. Timing Hip Fracture Surgery in Acute Heart Failure Patients 3.1. Host: Hip fractures in frail patients with acute heart failure present a classic timing dilemma. Should we delay surgery for diuresis and stabilization, or proceed immediately to minimize complications like delirium and pneumonia? 3.2. Guest: It's a clinical tightrope. Delay advocates cite quadrupled mortality in unoptimized heart failure, aligning with ACS-TQIP guidelines recommending up to 48 hours for stabilization, especially if oxygen needs and fluid overload are significant. 3.3. Host: Yet, the HIP ATTACK trial supports expedited surgery, showing lower mortality and fewer adverse events with delays under 24 hours. How do teams decide, especially when physiologic status is borderline? 3.4. Guest: Fluid balance thresholds and real-time monitoring are critical. Multidisciplinary protocols, involving cardiology and anesthesia, help stratify who benefits from delay versus urgent operation. Mortality heatmaps increasingly guide these nuanced calls. 3.5. Host: Could AI-driven risk calculators or remote monitoring soon tip the scales by predicting which patients will truly benefit from delay? 3.6. Guest: Absolutely. As decision-support tools mature, they’ll help personalize timing, integrating more granular physiologic data than blanket ...
    Show More Show Less
    9 mins